Weill Cornell Medicine Receives $2 Million for Immunotherapy Research

Weill Cornell Medicine Receives $2 Million for Immunotherapy Research

Weill Cornell Medicine has announced a $2 million gift from Ellen and Gary Davis in support of research on a cancer treatment strategy that uses immune cells to fight the disease.

The gift will launch the Ellen and Gary Davis Immune Monitoring Core, a research infrastructure that will serve as a repository for patient tumor samples, genomic sequencing, and bioinformatics, providing centralized, quantitative patient data that investigators can use to advance their research into immunotherapy. In addition, a portion of the gift will fund research collaborations between investigators at Weill Cornell Medicine, Cornell University, and Cornell Tech.

Ellen Davis, an investor in and advisor for early-stage businesses, joined the Weill Cornell Medicine Board of Overseers in 2015 and serves on its special committee on research and its membership and nominating committees. Gary Davis is CEO of DKR Capital Partners, an investment advisory firm primarily engaged in the hedge fund and private equity markets. A Cornell trustee since 2012, he is a member of the board's executive committee and co-chair of the development committee, as well as a vice chair of the investment committee and member of the finance committee.

The Davises' legacy of philanthropy at Cornell University includes endowment gifts for the Gary S. Davis Professorship of Government and the Gary and Ellen Davis Curator of Photography at the Herbert F. Johnson Museum of Art in Ithaca, and a gift to establish a joint fellowship at the Meinig School of Biomedical Engineering and Weill Cornell Medicine to advance research into epilepsy.

"We are extremely grateful to Ellen and Gary, whose strategic gift establishes an important foundation for immunotherapy research that is befitting of the treatment's promise," said Jessica M. Bibliowicz, chair of the Weill Cornell Medicine Board of Overseers. "Ellen and Gary's generous support will augment our growing immunotherapy program, bolster our rich research communities at Weill Cornell Medicine and Cornell University, and bring us closer to eliminating cancer."

"Ellen and Gary Davis Immune Monitoring Core Established at Weill Cornell Medicine." Weill Cornell Medicine Press Release 10/25/2016.